Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammograph

Radiology

Volumn 250, Issue 2, 2009, Pages 398-406

  Karathanasis, Efstathios ^a   Suryanarayanan, Sankararaman ^b   Balusu, Sri R ^a   McNeeley, Kathleen ^a   Sechopoulos, Ioannis ^b   Karellas, Andrew ^b,d   Annapragada, Ananth V ^c   Bellamkonda, Ravi V ^a  

^a Emory University   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IODIXANOL; LIPOSOME; CONTRAST MEDIUM; DIAGNOSTIC AGENT; IODINE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIGITAL MAMMOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG UPTAKE; FEMALE; IMAGING SYSTEM; NANOPROBE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIATION DOSE; RAT; SIGNAL DETECTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; ANALYSIS OF VARIANCE; ANIMAL; EXPERIMENTAL NEOPLASM; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MONTE CARLO METHOD; PATHOLOGY; RADIOGRAPHY; REGRESSION ANALYSIS;

ANALYSIS OF VARIANCE; ANIMALS; CONTRAST MEDIA; DOXORUBICIN; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IODINE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMOGRAPHY; MONTE CARLO METHOD; NANOPARTICLES; RATS; REGRESSION ANALYSIS;

EID: 61749095523     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2502080801     Document Type: Article

References (36)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5(3):161-171.
2. Service RF. Materials and biology: nanotechnology takes aim at cancer. Science 2005; 310(5751):1132-1134.
3. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin- bound paclitaxel compared with polyethyl- ated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23(31):7794-7803.
4. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature 1996;380(6574):561-562.
5. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanopar- ticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006;7(8):657- 667.
6. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995;267(5202):1275- 1276.
7. U.S. National Institutes of Health. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/. Accessed December 12, 2007.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med1995;1(1):27-31.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801):249-257.
10. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46(1-3):169-185.
11. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65(1-2):271- 284.
12. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54(13):3352-3356.
13. WolffAC. Liposomal anthracyclines and new treatment approaches for breast cancer. Oncologist 2003;8(suppl 2):25-30.
14. Fukumura D, Jain RK. Tumor microenviron- ment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101(4):937-949.
15. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad SciUSA1998; 95(8):4607-4612.
16. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93(25): 14765-14770.
17. Mukundan S Jr, Ghaghada KB, Badea CT, et al. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol 2006;186(2):300-307.
18. Hubbell JH, Seltzer SM. Tables ofx-ray mass attenuation coefficients and mass energy- absorption coefficients. http: //physics.nist.gov/PhysRefData/ XrayMassCoef/cover.html. Accessed December 5, 2007.
19. Ullman G, Sandborg M, Dance DR, Yaffe M, Alm Carlsson G. A search for optimal x-ray spectra in iodine contrast media mammography. Phys Med Biol 2005;50(13):3143-3152.
20. Flynn MJ, Samei E. Experimental comparison of noise and resolution for 2k and 4k storage phosphor radiography systems. Med Phys 1999;26(8):1612-1623.
21. Sechopoulos I, Suryanarayanan S, Vedantham S, D'Orsi C, Karellas A. Computation of the glandular radiation dose in digital tomosynthesis of the breast. Med Phys 2007;34(1):221-232.
22. Boone JM. Normalized glandular dose (DgN) coefficients for arbitrary X-ray spectra in mammography: computer-fit values of Monte Carlo derived data. Med Phys 2002; 29(5):869-875.
23. McNeeley KM, Annapragada A, Bellamkonda RV. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting fo- late receptors of glioma. Nanotechnology 2007; 18:385101.
24. Jain A, Kim YT, McKeon RJ, Bellamkonda RV. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006;27(3):497-504.
25. Brown BW, Atkinson EN, Bartoszynski R, Thompson JR, Montague ED. Estimation of human tumor growth rate from distribution
26. of tumor size at detection. J Natl Cancer Ins 1984;72(1):31-38.
27. Park JW, Hong K, Kirpotin DB, et al. Anti HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8(4):1172-1181.
28. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidi nanoparticles does not increase tumor local ization but does increase internalization in animal models. Cancer Res 2006;66(13) 6732- 6740.
29. Saucier JM, Yu J, Gaikwad A, Coleman RL Wolf JK, Smith JA. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract 2007;13(1):39- 45.
30. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing lipo somes for delivery of chemotherapeuti agents to solid tumors. Pharmacol Rev 1999 51(4):691-743.
31. Karathanasis E, Chan L, Balusu SR, et al Multifunctional nanocarriers for mammo graphic quantification of tumor dosing and prognosis of breast cancer therapy. Biomaterials 008;29:4815- 4822.
32. Harrington KJ, Mohammadtaghi S, Uste PS, et al. Effective targeting of solid tumor in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Can cer Res 2001;7(2):243-254.
33. Parish CR, Freeman C, Brown KJ, Franci DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumo growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59(14):3433-3441.
34. Huang SK, Lee KD, Hong K, Friend DS Papahadjopoulos D. Microscopic localization ofsterically stabilized liposomes in colon car cinoma-bearing mice. Cancer Res 1992 52(19):5135-5143.
35. Damert A, Machein M, Breier G, et al. Up regulation ofvascular endothelial growth fac tor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms Cancer Res 1997;57(17):3860-3864.
36. Takano S, Yoshii Y, Kondo S, et al. Concentra tion of vascular endothelial growth factor in the serum and tumor tissue ofbrain tumor patients Cancer Res 1996;56(9):2185-2190.